Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0IKWPY)
ADC Name
RFT5-SMPT-dgA
Synonyms
Monoclonal antibody RFT5-ricin chain A conjugate; RFT5 ricin A; RFT5-dgA; RFT5-ricin A; RFT5ricin A
   Click to Show/Hide
Organization
Koeln University, Texas University
Drug Status
Phase 1
Antibody Name
Anti-CD25 mAb RFT5
  Antibody Info 
Antigen Name
Interferon-stimulated gene 20 kDa protein (ISG20)
  Antigen Info 
Payload Name
Deglycosylated ricin A-chain (dgA)
  Payload Info 
Linker Name
Succynimidyloxycarbonyl-alpha-methyl-alpha- (2-pyridyl-dithio) toluene (SMPT)
  Linker Info 
2027 Update
General Information of The ADMET Data Related to This ADC
Absorption
Click To Hide/Show 30 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Maximum Observed Concentration (Cmax) 0.78 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 1, 5 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 3.16 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 1, 5 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 5.49 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 2, 5 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 19.66 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 2, 5 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 0.2 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 3, 5 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 1.12 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 3, 5 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 1.23 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 4, 10 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 1.49 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 4, 10 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 7.81 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 5, 10 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 132.98 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 5, 10 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 7 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 6, 10 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 112.93 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 6, 10 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 7.94 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 7, 15 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 44.19 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 7, 15 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 3.65 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 8, 15 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 33.46 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 8, 15 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 7.44 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 9, 15 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 57.3 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 9, 15 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 2.12 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 10, 15 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 16.78 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 10, 15 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 6.27 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 11, 15 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 89.02 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 11, 15 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 6.91 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 12, 15 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 76.19 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 12, 15 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 9.7 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 13, 20 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 68.51 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 13, 20 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 9.57 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 14, 20 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 95.36 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 14, 20 mg/m2.
 [1]
Maximum Observed Concentration (Cmax) 8.8 ug/mL
Peak serum concentration, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 15, 20 mg/m2.
 [1]
Area Under the Concentration-Time Curve (AUC) 80.93 mg·h/L
Maximum area under the concentration versus time curve, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 15, 20 mg/m2.
 [1]
Excretion
Click To Hide/Show 30 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Elimination Half-Life (t1/2) 4.54 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 1, 5 mg/m2.
 [1]
Clearance (CL) 4700 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 1, 5 mg/m2.
 [1]
Elimination Half-Life (t1/2) 4.04 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 2, 5 mg/m2.
 [1]
Clearance (CL) 410 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 2, 5 mg/m2.
 [1]
Elimination Half-Life (t1/2) 4.05 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 3, 5 mg/m2.
 [1]
Clearance (CL) 9386 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 3, 5 mg/m2.
 [1]
Elimination Half-Life (t1/2) 4.72 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 4, 10 mg/m2.
 [1]
Clearance (CL) 5853 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 4, 10 mg/m2.
 [1]
Elimination Half-Life (t1/2) 9.73 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 5, 10 mg/m2.
 [1]
Clearance (CL) 60 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 5, 10 mg/m2.
 [1]
Elimination Half-Life (t1/2) 6.57 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 6, 10 mg/m2.
 [1]
Clearance (CL) 90 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 6, 10 mg/m2.
 [1]
Elimination Half-Life (t1/2) 7.83 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 7, 15 mg/m2.
 [1]
Clearance (CL) 302 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 7, 15 mg/m2.
 [1]
Elimination Half-Life (t1/2) 7.16 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 8, 15 mg/m2.
 [1]
Clearance (CL) 452 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 8, 15 mg/m2.
 [1]
Elimination Half-Life (t1/2) 3.98 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 9, 15 mg/m2.
 [1]
Clearance (CL) 391 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 9, 15 mg/m2.
 [1]
Elimination Half-Life (t1/2) 3.97 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 10, 15 mg/m2.
 [1]
Clearance (CL) 917 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 10, 15 mg/m2.
 [1]
Elimination Half-Life (t1/2) 10.53 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 11, 15 mg/m2.
 [1]
Clearance (CL) 136 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 11, 15 mg/m2.
 [1]
Elimination Half-Life (t1/2) 4.9 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 12, 15 mg/m2.
 [1]
Clearance (CL) 226 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 12, 15 mg/m2.
 [1]
Elimination Half-Life (t1/2) 5.3 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 13, 20 mg/m2.
 [1]
Clearance (CL) 522 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 13, 20 mg/m2.
 [1]
Elimination Half-Life (t1/2) 8.41 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 14, 20 mg/m2.
 [1]
Clearance (CL) 81 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 14, 20 mg/m2.
 [1]
Elimination Half-Life (t1/2) 5.52 h
Maximum elimination half-life, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 15, 20 mg/m2.
 [1]
Clearance (CL) 235 mL/h
Maximum clearance, Pharmacokinetic Parameters of RFT5-SMPT-dgA, Patient 15, 20 mg/m2.
 [1]
References
Ref 1 A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma